Physician profile
Wei Gui
NPI 1679980882
$8,171.90
in general payments reported to CMS, 2019-2025
23 companies · $1,205 in 2025
The $1,205 reported for 2025 was more than what 81% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,980 · 2020: $102 · 2021: $388 · 2022: $862 · 2023: $3,045 · 2024: $590 · 2025: $1,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,750 · Food and Beverage: $2,090.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,750.00 |
| Food and Beverage | $2,089.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,577.87 | 2019-2025 | Rocklatan, Rhopressa, Tryptyr |
| Regeneron Pharmaceuticals, INC. | $806.34 | 2019 | |
| Genentech USA, INC. | $687.94 | 2021-2025 | Vabysmo |
| Novartis Pharmaceuticals Corporation | $613.65 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $487.94 | 2019-2025 | Eylea Hd |
| Sun Pharmaceutical Industries INC. | $361.53 | 2021-2025 | |
| Amgen INC. | $283.46 | 2025 | Tepezza |
| Dutch Ophthalmic, USA | $166.83 | 2019 | |
| Sight Sciences, INC. | $156.04 | 2024 | Omni Surgical System |
| Abbvie INC. | $125.00 | 2025 | |
| Bausch & Lomb Americas INC. | $125.00 | 2025 | Vyzulta |
| Glaxosmithkline, LLC. | $125.00 | 2022 | |
| Spark Therapeutics, INC. | $125.00 | 2021 | |
| Oyster Point Pharma, INC. | $120.67 | 2023 | Tyrvaya |
| Astellas Pharma US INC | $120.35 | 2023-2025 | Izervay |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $120.25 | 2025 | Xdemvy |
| Aimmune Therapeutics, INC. | $49.05 | 2025 | Zenpep |
| Apellis Pharmaceuticals, INC. | $30.18 | 2024 | Syfovre |
| Alimera Sciences, INC. | $24.77 | 2023 | Iluvien |
| Genentech, INC. | $17.78 | 2024 | Vabysmo |
| Glaukos Corporation | $17.49 | 2023 | |
| Coherus Oncology, INC. | $15.36 | 2022 | |
| Boston Scientific Corporation | $14.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Gui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.